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Abstract 
Background: Although the loop-diuretic furosemide is widely employed in critically ill patients with known long-
term effects on plasma electrolytes, accurate data describing its acute effects on renal electrolyte handling and the 
generation of plasma electrolyte alterations are lacking. We hypothesized that the long-term effects of furosemide on 
plasma electrolytes and acid–base depend on its immediate effects on electrolyte excretion rate and patient clinical 
baseline characteristics. By monitoring urinary electrolytes quasi-continuously, we aimed to verify this hypothesis in a 
cohort of surgical ICU patients with normal renal function.
Methods: We retrospectively enrolled 39 consecutive patients admitted to a postoperative ICU after major surgery, 
and receiving single low-dose intravenous administration of furosemide. Urinary output, pH, sodium [Na+], potassium 
[K+], chloride [Cl−] and ammonium [NH4
+] concentrations were measured every 10 min for three to 8 h. Urinary anion 
gap (AG), electrolyte excretion rate, fractional excretion (Fe) and time constant of urinary [Na+] variation (τNa+) were 
calculated.
Results: Ten minutes after furosemide administration (12 ± 5 mg), urinary [Na+] and [Cl−], and their excretion rates, 
increased to similar levels (P < 0.001). After the first hour, urinary [Cl−] decreased less rapidly than [Na+], leading to 
a reduction in urinary AG and pH and an increment in urinary [NH4
+] (P < 0.001). Median urinary [Cl−] over the first 
3-h period was higher than baseline urinary and plasmatic [Cl−] (P < 0.001). During the first 2 h, difference between 
FeCl− and FeNa+ increased (P < 0.05). Baseline higher values of central venous pressure and FeNa+ were associated 
with greater increases in FeNa+ after furosemide (P = 0.03 and P = 0.007), whereas higher values of mean arterial and 
central venous pressures were associated with a longer τNa+ (P < 0.05). In patients receiving multiple administrations 
(n = 11), arterial pH, base excess and strong ion difference increased, due to a decrease in plasmatic [Cl−].
Conclusions: Low-dose furosemide administration immediately modifies urinary electrolyte excretion rates, likely in 
relation to the ongoing proximal tubular activity, unveiled by its inhibitory action on Henle’s loop. Such effects, when 
cumulative, found the bases for the long-term alterations observed. Real-time urinary electrolyte monitoring may 
help in tailoring patient diuretic and hemodynamic therapies.
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Background
The loop-diuretic furosemide is one of the most frequent 
pharmacological treatments employed in intensive care 
unit (ICU) [1, 2]. Although generally accepted indications 
include extravascular fluid accumulation and reduced uri-
nary output [3], in the last decade much attention has been 
paid on the role of furosemide in the prevention, treatment 
[4], and early detection [5] of acute kidney injury (AKI). 
Nonetheless, data supporting these indications are still con-
troversial, and general recommendations regarding furo-
semide administration are not yet clearly standardized [6, 7].
The most frequent method of administration in ICU is 
the intravenous bolus [1, 8]. The rationale for such admin-
istration relies on its mechanism of action, directly inhib-
iting the sodium–potassium-2 chloride (Na+/K+/2Cl−) 
cotransport of the think ascending limb of Henle’s loop 
(NKCC2) [9, 10]. Consequently to such inhibition, in 
patients with normal renal function, furosemide leads to 
the excretion of up to 20–25  % of the filtered Na+, and, 
in parallel, to an alteration of urinary excretion of other 
main electrolytes [6]. Moreover, its administration is often 
associated with a variable effect on urinary output and 
fractional excretion of Na+ [2], and with alterations in 
plasma electrolytes concentrations and acid–base equilib-
rium [11, 12], often leading to metabolic alkalosis.
Despite its extensive use, accurate data describing the 
physiological effects of furosemide in patients admitted 
to intensive care unit (ICU) are still lacking [7]. Except 
for few reports describing its hemodynamics and neu-
rohumoral effects [13, 14], no studies have accurately 
investigated heretofore the acute and immediate effects 
of furosemide on renal electrolytes handling, which may 
affect both the renal response to its administration and 
the associated alterations in acid–base equilibrium.
In preliminary studies, we have recently employed a 
urinary analyzer (K.IN.G.®, Kidney Instant Monitoring®), 
allowing quasi-continuous measurement of urinary pH 
and urinary concentrations of Na+, K+, Cl− and ammo-
nium (NH4+) [15]. Therefore, by retrospectively analyz-
ing the minute-by-minute urinary electrolyte profile, we 
aimed first to elucidate, in a cohort of ICU patients with 
normal renal function, the acute renal response to a low-
dose intravenous bolus of furosemide and its correlation 
with patient clinical characteristics. Second, we aimed to 
investigate the relationship between urinary electrolyte 
excretion and the development of metabolic alkalosis, 
as the most frequently observed alteration of acid-base 
associated with loop-diuretic administration.
Methods
Study population
We retrospectively analyzed patients admitted between 
November 2009 and June 2010 to the postoperative ICU 
of our Institution after major surgery and connected to 
the urinary analyzer K.IN.G.® (Kardia s.r.l., Milan, Italy). 
As previously reported [15], we preliminary investigated 
the applicability of the analyzer K.IN.G.® in a cohort of 
200 ICU patients. Inclusion criteria of the current study 
were intravenous administration of furosemide during 
ICU stay, as decided by the attending physician for clini-
cal purposes, the connection of the patient to the urinary 
analyzer K.IN.G.® and a period of at least 3  h of uri-
nary monitoring after the administration. We excluded 
patients with less than 18 years of age, chronic or acute 
renal failure, admitted after liver transplantation or low-
genitourinary tract surgery, or receiving intra-operatively 
diuretics. The study was compliant with the 1975 Decla-
ration of Helsinki and was approved by the local Institu-
tional Review Board (study #1961, on 09/07/2013, Ethical 
Committee of Fondazione IRCCS Ca’ Granda—Ospedale 
Maggiore Policlinico, Milan, Italy), who waived patient 
consent based upon the observational nature of the study.
Study design
We divided the study population into three different 
groups based upon the duration of urinary monitoring. 
The first group included all patients enrolled (single-dose 
group), in which observation period lasted at least 3  h. 
The second group included patients in whom observa-
tion period lasted up to 8 h (long-term group). The third 
group included patients who received two or more doses 
of furosemide during urinary monitoring (multiple-dose 
group).
Data collection
We collected data regarding patient demographic, anam-
nestic, baseline clinical characteristics and dosage of 
furosemide administered. Moreover, we retrieved data 
regarding hemodynamics, respiratory and renal function-
ality, arterial blood gas and laboratory analyses just before 
the administration of furosemide. For patients included 
in the multiple-dose group, plasmatic electrolyte concen-
trations and parameters of acid–base equilibrium were 
obtained before the first and after the last administration. 
Alterations of acid base equilibrium in patients receiving 
multiple furosemide administrations were evaluated by 
using the Stewart approach to acid–base [18] identifying 
correlations between electrolyte concentrations and acid–
base balance variations. The datasets supporting the con-
clusions of this article are included within the article (and 
its additional files—see Additional files 1, 2 and 3).
Urinary analyzer K.IN.G. ®
All the patients included in the study were connected, 
through their urinary catheter, to the urinary analyzer 
K.IN.G.® before furosemide administration. This analyzer 
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provides quasi-continuous measurements (every 10 min) 
of urinary pH, concentrations of Na+, K+, Cl− and NH4+, 
as well as urinary output [15]. The measuring principle 
of the analyzer relies on the potentiometric method, by 
means of ion-sensible sensors. For this reason, analyses 
were obtained without any dilution process.
Calculations and definitions
We calculated urinary excretion rate of electrolytes from 
urinary output and electrolyte concentrations measured 
by the urinary analyzer. Glomerular filtration rate (GFR) 
was estimated with the standard Cockcroft-Gault for-
mula [16]. Based upon their plasmatic concentrations, 
and their urinary excretion rate, we calculated the frac-
tional excretion of Na+ (FeNa+), Cl− (FeCl−), and K+ 
(FeK+) during study period, as follows:
where FeE denotes the fractional excretion of the electro-
lyte of interest, EU its urinary excretion rate, and [E]PL its 
plasmatic concentration.
Urinary anion gap (AG) was defined as the differ-
ence between urinary concentrations of all measured 
cations (i.e., [Na+] and [K+]) and anions (i.e., [Cl−]) 
[17], whereas plasmatic strong ion difference (SID) as 
the difference between plasmatic concentration of all 
measured cations (i.e., [Na+] and [K+]) and anions (i.e., 
[Cl−] and lactate) [18]. Time constant of urinary [Na+] 
variation (τNa+U) was mathematically defined as the time 
required observing a decrease in urinary [Na+] down to 
approximately 63 % of its initial increase after furosem-
ide administration.
Statistical analysis
Comparison of baseline parameters was performed by 
Student’s t test, the Mann–Whitney rank sum test, the 
Chi-square test or Fisher’s exact test, as appropriate. 
Variations in urinary pH and electrolyte concentra-
tions over time were analyzed with one-way or two-way 
ANOVA for repeated measurements, as appropriate. 
Comparison between linear regressions was performed 
by employing the test for equal intercept. To investigate 
the relationship between baseline clinical characteris-
tics and renal response to furosemide administration, 
study population was divided according to median val-
ues of hemodynamic and renal functional parameters, as 
well as according to the median value of τNa+U. Data are 
expressed as mean ± SD, or median (25th–75th percen-
tile), as appropriate. Statistical significance was defined 
as P < 0.05. Analysis was performed by using Sigma Plot 
12.5 (Systat Software) and SAS 9.2 computer software 
(SAS Institute).
FeE = EU/
(
GFR/1000 × [E]PL
)
Results
Study population
We enrolled in the study 39 consecutive patients (single-
dose group). In 24 patients, observation was prolonged 
up to 8 h (long-term group), whereas in 11 patients study 
period included also subsequent administrations (multi-
ple-dose group, for a total period of 22 ± 13 h) (Table 1). 
The dosage of furosemide administered as a single intra-
venous bolus averaged 12  ±  5  mg. All patients were 
spontaneously breathing during the entire study period.
Urinary pH and electrolytes after furosemide 
administration as single bolus
After furosemide administration, urinary output mark-
edly increased, commencing 10 min after the administra-
tion (P < 0.05) until the first 100 min (Additional file 4: 
Figure S1). In parallel, urinary [Na+] and [Cl−] rapidly 
increased from 54 (38–88) to 140 (122–159) mEq/l and 
from 117 (87–134) to 147 (132–163) mEq/l, respectively 
(Fig. 1a, b). In contrast, urinary [K+] fell from 52 (38–77) 
to 29 (18–56) mEq/L (Fig. 1c) (P < 0.001 vs. baseline, for 
all). After its initial increase, both urinary [Na+] and [Cl−] 
slowly decreased toward baseline values, although uri-
nary [Cl−] reduction over time appeared less rapid than 
that of urinary [Na+]. After its prompt increase, urinary 
AG decreased as compared to baseline values (P < 0.001 
vs. baseline, Fig.  1d). In parallel, urinary pH decreased 
over time, starting 50  min after furosemide administra-
tion (P < 0.001 vs. baseline, Fig. 1e), and urinary [NH4+], 
progressively increased toward the end of the observa-
tion period (P < 0.001 vs. baseline, Fig. 1f ). Median uri-
nary [Na+] and [Cl−] over the entire 3-h period increased 
from baseline to similar values (P =  0.09 for electrolyte 
comparison, and P  <  0.001 for comparison with base-
line values; Table 2). Of note, median urinary [Cl−] after 
furosemide administration was significantly higher than 
baseline values of plasmatic [Cl−] (135 [127–149] vs. 107 
[104–110] mEq/l, P < 0.001).
Urinary excretion rates of Na+, Cl−, K+ and NH4+ 
increased over time as compared to baseline values 
(Table  2). These increments appeared significantly dif-
ferent within 30  min after the administration (P  <  0.05 
for all). FeNa+ and FeCl− significantly increased within 
30  min and remained elevated for 2  h. Hourly values of 
FeNa+, both at baseline and after furosemide admin-
istration, were linearly associated with values of FeCl− 
(r2 = 0.88 and r2 = 0.95, respectively, P < 0.001 for both), 
but such relationship significantly shifted upward after the 
administration (P = 0.002 for intercept comparison; Addi-
tional file 4: Figure S2). Moreover, the difference between 
FeCl− and FeNa+ significantly increased during the first 
2 h after furosemide administration (P < 0.05, Fig. 2).
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Short‑term variability of furosemide on urinary Na+ 
excretion rate
Although urinary [Na+] and Na+ excretion rate increased 
in all patients, these effects appeared widely variable 
(Fig.  3), ranging from 0.7 to 18.1  % for FeNa+ within 
the first hour, due to the early variation in urinary out-
put, and from 13 to 201 mEq/l for urinary [Na+] at the 
third hour, denoting a variable reduction rate after its 
first increment. Such variability did not depend on the 
dose of furosemide administered (P = 0.28 and P = 0.54, 
respectively, for FeNa+-dose and urinary [Na+]-dose 
interactions).
When the study population was divided according to 
baseline hemodynamics and renal functional param-
eters (Additional file  4: Table S1), patients with higher 
CVP (>8 mmHg) and FeNa+ at baseline (>0.4%) showed 
a greater increment in FeNa+ after furosemide as com-
pared to patients with lower CVP and FeNa+, respec-
tively (P =  0.03 and P =  0.007 for interaction; Fig.  4). 
When study population was divided according to the 
median value of τNa+U, patients with a slower decrease 
in urinary [Na+] over time showed a higher base-
line MAP and CVP as compared to those with a faster 
decrease (Additional file 4: Table S2).
Long‑term observation
The increase in urinary [Na+] and [Cl−] observed after 
furosemide administration lasted mainly 3 h, as median 
urinary concentrations of both electrolytes achieved 
baseline values around the third hour (long-term group, 
n = 24, Additional file 4: Table S3 and Fig. 5). A similar 
time course was observed for urinary [NH4+]. Urinary 
excretion rate of all the electrolytes assessed signifi-
cantly increased as compared to baseline values only 
within the first 3 h (P < 0.05 vs. baseline values), return-
ing toward baseline values in the subsequent hours. 
Notably, median values of urinary [Cl−] over the entire 
8-h period were higher than baseline values of plas-
matic [Cl−] (125 [112–132] vs. 107 [105–109] mEq/l, 
P = 0.02).
Table 1 Characteristics of the patients at baseline
Data are reported as mean ± standard deviation, or numbers (%), as appropriate
BMI body mass index, RAAS renin–angiotensin–aldosterone system, CVP central venous pressure, PCO2 partial pressure of carbon dioxide, Na
+ sodium, K+ potassium, 
Cl− chloride, SID strong ion difference, BE base excess
a Data on CVP were available for 37 patients, whereas data on creatinine clearance, arterial pH, arterial CO2, lactate, SID and arterial BE were available for 34 patients
Characteristics Single‑dose group
(n = 39)
Long‑term group
(n = 24)
Multiple‑dose group
(n = 11)
Age (years) 69 ± 11 67 ± 13 69 ± 16
Sex female—no. (%) 15 (38) 7 (29) 4 (36)
BMI (kg/m2) 26 ± 5 26 ± 5 25 ± 3
Causes of admission—no. (%)
 Gastrointestinal surgery 12 (31) 4 (17) 5 (46)
 Liver surgery 6 (15) 5 (21) 2 (18)
 Thoracic surgery 16 (41) 12 (50) 2 (18)
 Others 5 (13) 3 (12) 2 (18)
Diuretics 5 (13) 2 (8) 2 (18)
Beta-blockers 6 (15) 2 (8) 2 (18)
RAAS inhibitors 2 (5) 1 (4) 0 (0)
Length of study period (hours) 3 8 22 ± 13
Furosemide dose (mg) 12 ± 5 12 ± 5 38 ± 17
CVP (mmHg)a 8.4 ± 3.2 7.7 ± 3.1 10.3 ± 3.1
Diuresis (ml/kg/h) 0.6 ± 0.3 0.8 ± 0.5 0.9 ± 0.3
Creatinine clearance (ml/min)a 83 ± 35 73 ± 35 73 ± 44
Arterial pHaa 7.42 ± 0.04 7.43 ± 0.03 7.42 ± 0.05
Arterial PCO2 (mmHg)
a 39.9 ± 3.9 39.6 ± 3.6 40.5 ± 4.5
Na+ (mEq/L) 138 ± 3 138 ± 3 138 ± 3.0
K+ (mEq/L) 4.1 ± 0.4 4.2 ± 0.4 3.8 ± 0.4
Cl− (mEq/L) 107.0 ± 3.6 107 ± 3 109 ± 4.0
Lactate (mEq/L)a 1.1 ± 0.5 1.1 ± 0.5 1.2 ± 0.7
SID (mEq/L)a 34.1 ± 2.6 33.3 ± 2.1 32.0 ± 1.9
Arterial BE (mmol/L)a 1.6 ± 2.6 2.0 ± 2.9 1.8 ± 3.1
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Fig. 1 Urinary sodium (Na+, a), chloride (Cl–, b), potassium (K+, c) concentrations, anion gap (AG, d), pH (e) and ammonium (NH4
+, f) concentration 
every 10 min before and after the administration of an intravenous bolus of furosemide in the overall study population (single-dose group, group 
n = 39). Data are expressed as median and interquartile range. Time 0 (baseline) denotes the time of furosemide administration. One-way ANOVA 
for repeated measurements was performed (P < 0.001 for time effect; *P < 0.05 vs. baseline, time 0)
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Table 2 Urinary electrolyte, pH and anion gap profile at baseline and during 3-h furosemide administration
Data are reported as median value and interquartile ranges of values recorded during 30-min periods before (baseline) and after the intravenous administration of 
furosemide in the overall study population (single-dose group, n = 39). Median 3 h denotes median values of parameters recorded, as average, during the entire 3-h 
period
Na
+
U
 urinary sodium, K+
U
 urinary potassium, Cl−
U
 urinary chloride, NH+
4
U urinary ammonium, AGU urinary anion gap, Fe fractional excretion
a Data on Diuresis reported as between 0–30 min and 60–90 min refer to the total time included between 0–60 min and 60–120 min, respectively
b Data on FeNa+, FeK+ and FeCl– were available for 34 patients. One-way ANOVA for repeated measurements was performed. * P < 0.05 versus baseline
Variable Baseline 0–30 min 30–60 min 60–90 min 90–120 min 120–180 min P Median 3 h
[Na+]U (mEq/L) 57 (31–88) 142 (130–158)* 141 (127–151)* 134 (113–143)* 116 (97–129)* 91 (105–136) <0.001 134 (116–142)
[K+]U (mEq/L) 56 (39–79) 22 (16–30)* 19 (17–26)* 26 (21–33)* 32 (25–38)* 36 (29–44)* <0.001 24 (19–32)
[Cl−]U (mEq/L) 118 (84–131) 137 (130–153)* 137 (129–155)* 139 (127–156)* 134 (123–152)* 131 (106–142) <0.001 135 (127–149)
[NH4
+]U (mEq/L) 7.0 (1.5–11.7) 6.0 (4.2–8.6) 6.7 (4.7–9.3) 8.6 (6.6–11.8)* 9.8 (6.9–14.2)* 10.3 (6.8–13.0)* <0.001 7.6 (5.8–9.4)
Diuresis (ml/
kg/h)
1.0 (0.5–1.3) 5.4 (3.4–7.7)* 4.1 (3.0–5.9)* 2.3 (1.7–3.6)* 1.5 (1.1–2.5)* 1.1 (0.8–1.6) <0.001 2.7 (2.0–3.5)
Diuresis (ml/h)a 53 (34–76) 325 (221–394)* 114 (95–179)* 71 (53–100) <0.001 528 (413–652)
AGU (mEq/L) 17 (−4 to 42) 28 (17–40)* 19 (11–31) 17 (0–27) 11 (−6 to 26) 5 (−7 to 23)* <0.001 20 (8–29)
Na
+
U
 (µEq/kg/
min)
0.8 (0.2–1.5) 13.3 (8.0–19.8)* 9.6 (5.9–13.7)* 5.1 (2.9–7.0)* 2.9 (1.9–5.4)* 1.7 (0.9–3.1) <0.001 6.6 (4.0–8.4)
K
+
U
 (µEq/kg/min) 0.8 (0.5–1.0) 1.9 (1.3–2.5)* 1.4 (1.0–1.7)* 1.1 (0.8–1.4)* 0.8 (0.6–1.0) 0.7 (0.5–1.0) <0.001 1.1 (1–1.3)
Cl
−
U
 (µEq/kg/
min)
1.6 (0.8–2.5) 12.9 (8.2–18.4)* 10.1 (6.4–13.7)* 5.9 (3.8–7.9)* 3.5 (2.6–5.9)* 2.3 (1.7–3.8) <0.001 7 (4.2–8.2)
NH
+
4 U
 (µEq/kg/
min)
0.09 (0.01–0.22) 0.45 (0.30–
0.94)*
0.45 (0.32–
0.62)*
0.35 (0.21–
0.50)*
0.25 (0.15–
0.39)*
0.20 (0.13–0.29) <0.001 0.34 (0.21–0.47)
FeNa+ (%)b 0.4 (0.2–1.1) 8.2 (6.1–12.5)* 6.6 (4.1–10.0)* 3.5 (1.8–6.4)* 1.8 (1.0–4.4)* 0.9 (0.6–2.4) <0.001 3.9 (2.7–5.7)
FeK+ (%)b 18 (13–35) 47 (38–65)* 35 (25–43)* 28 (17–35) 22 (14–29) 17 (9–25) <0.001 29 (21 – 35)
FeCl− (%)b 1.4 (0.6–2.3) 10.4 (7.1–16.4)* 8.4 (6.5–12.5)* 4.5 (3.4–9.2)* 2.7 (1.9–5.0)* 1.8 (1.1–3.7) <0.001 5.5 (4.1–8.1)
*
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Fig. 2 Difference between chloride and sodium fractional excretion 
at baseline and after furosemide administration. Data are reported 
as hourly median, interquartile ranges, and 5° and 95° percentile 
range of the difference between fractional excretion of chloride and 
fractional excretion of sodium before and after the administration of 
an intravenous bolus of furosemide in the overall study population 
(single-dose group, group n = 39). Baseline denotes the time of furo-
semide administration. One-way ANOVA for repeated measurements 
was performed (P < 0.001 for time effect; *P < 0.05 vs. baseline, time 
0). Na+ sodium, Cl− chloride
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Fig. 3 Hourly time course of fractional excretion of sodium (FeNa+, 
dark bar) and urinary sodium concentration (Na+, open bar) before 
and after the administration of an intravenous bolus of furosemide in 
the overall study population (single-dose group, group n = 39). Data 
are expressed as median value, interquartile range, and 5° and 95° 
percentile range. Time 0 (baseline) denotes the time of furosemide 
administration. One-way ANOVA for repeated measurements was 
performed (P < 0.001 for time effect; *P < 0.001 vs. baseline, time 0)
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In the subgroup of patients receiving multiple admin-
istrations (multiple-dose group, n =  11), median urinary 
[Na+] and [Cl−] during furosemide administration were 
higher than baseline values (P  <  0.001 and P  =  0.03, 
respectively; Additional file  4: Table S4). Similar results 
were observed analyzing the respective variations in 
urinary excretion rate. Moreover, while urinary [NH4+] 
did not change during furosemide administration, 
its excretion rate increased as compared to baseline 
(P = 0.002). Median urinary [Na+] and [Cl−] during the 
administration tended to be respectively lower and higher 
than their plasmatic concentrations at baseline (respec-
tively 128 [118–140] vs. 139 [135–142] mEq/l, P = 0.06, 
for Na+; 129 [108–133] vs. 110 [106–11] mEq/l, P = 0.06, 
for Cl−). In these patients, multiple administrations of 
furosemide were associated with an increase in arterial BE 
(P = 0.001), pH (P = 0.01) and plasmatic SID (P = 0.01), 
due to a reduction in plasmatic [Cl−] (P = 0.009, Table 3).
Discussion
Our study shows that intravenous administration of furo-
semide, even at low doses, in patients with relatively nor-
mal renal function, induces an immediate subverting of 
both normal urinary excretion rate and concentration of 
main electrolytes, which commences very rapidly, and 
may have subsequent long-term effects as an additive 
result of sequential administrations.
As a first alteration, in parallel with the rapid increase in 
urinary output, urinary [Na+] constantly increased up to a 
value close to plasma [Na+] (about 142 mEq/L, as average). 
Notably, such increase did not appear related to baseline 
urinary [Na+] before administration (ranging from 5.0 to 
166 mEq/L). Few studies have previously analyzed the time 
course of urinary [Na+] after furosemide administration, 
being limited to the cumulative natriuresis (over a 24-h 
period), or the average urinary [Na+] over a longer time 
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Fig. 4 Time course of hourly fractional excretion of sodium before 
and after intravenous furosemide administration in the overall study 
population (single-dose group, group n = 39), as divided according 
to the median value of central venous pressure at baseline (8; 6–11). 
Data are expressed as median value and interquartile ranges. Baseline 
denotes the time of furosemide administration. Two-way ANOVA for 
repeated measurements was performed (P < 0.001 for time effect; 
P < 0.001 for group effect; P = 0.03 for interaction; *P < 0.05 vs. base-
line, time 0). Na+ sodium, CVP central venous pressure
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Fig. 5 Long-term time course of urinary sodium and chloride concentration after furosemide administration. Urinary sodium (Na+, a) and chloride 
(Cl−, b) concentrations every 10 min before and after the administration of an intravenous bolus of furosemide in the subgroup of patients in which 
urinary monitoring lasted up to 8 h (long-term group, n = 24). Data are expressed as median and interquartile range. Time 0 (baseline) denotes the 
time of furosemide administration. One-way ANOVA for repeated measurements was performed (P < 0.001 for time effect; *P < 0.001 vs. baseline, 
time 0)
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[2, 19, 20]. In these investigations, urinary [Na+] appeared 
lower than that observed in our study (120–125 mEq/L), 
but similar, as average, to that measured over the 8-h 
period, as the possible dilution of the early peaked urinary 
[Na+] with its following reduction. Overall, the urinary 
[Na+] time profile highlights the action of loop-diuretics 
within the nephron. By inhibiting the cotransport NKCC2 
of the Henle’s loop, which generates the hyperosmolar gra-
dient of medullary interstitium [21], furosemide switches 
off acutely such generation, equilibrating the interstitial 
osmolality with that of plasma of the peri-tubular capillar-
ies. Therefore, pre-urine arriving to the distal tubules after 
Henle’s loop inhibition equilibrates with the medullary 
interstitial space, appearing similar to that of plasma.
Patients with higher values of CVP or FeNa+ showed 
a greater increment in FeNa+ after furosemide as com-
pared to those with lower values. Moreover, CVP was 
higher in patients presenting a slower decrease in urinary 
[Na+] over time (longer τNa+U), as compared to patients 
with a shorter τNa+U. Expansion of intravascular and right 
atrial volume have been consistently associated with the 
release into circulation of both atrial (ANP) and brain 
natriuretic (BNP) peptides, as a consequence of myo-
cardial stretch [22]. ANP/BNP are thought to promote 
natriuresis by inhibiting Na+ reabsorption in the med-
ullary collecting tubules [23], as well as in the proximal 
tubule [24, 25]. Although we did not directly measure 
serum ANP/BNP, we may speculate that the acute reset-
ting of the cotransport NKCC2-dependent hyperosmo-
lality of the Henle’s loop unveils the Na+-excretive ANP/
BNP-related state characterizing both the proximal and 
the medullary collecting tubules, especially in patients 
with greater blood volume expansion.
In parallel with the slow decrease in urinary [Cl−] and 
the urinary [Na+]–[Cl−] dissociation, we observed a late 
progressive increase in urinary [NH4+]. Renal ammo-
nia production predominantly derives from glutamine 
metabolism in proximal tubular cells [26, 27]. Moreover, 
pre-urinary NH4+ competes with K+ for the cotransport 
NKCC2, which is responsible for NH4+ reabsorption, and 
NH3/NH4+ recycling within the interstitial medulla [28]. 
It is conceivable that the late increase in urinary [NH4+] 
may be related to an increased aldosterone synthesis and 
release, enhancing the activity of the luminal H+-ATPase 
of type A intercalated cells [29], thus increasing the acidi-
fication of urine and the amount of NH3 transformed 
into NH4+ and trapped into the lumen [28, 30].
In the subgroup of patients receiving multiple admin-
istrations, we observed the development, in about 22 h, 
of mild metabolic alkalosis. Several studies have investi-
gated loop-diuretics-induced metabolic alkalosis, focus-
ing on its maintenance and recovery [31, 32], whereas 
few have investigated its generation. Traditionally, the 
generation of diuretic-induced metabolic alkalosis is 
considered as related to the contraction of extracellular 
fluid volume and the consequent increase in HCO3− con-
centration [33]. In contrast, recent studies have clearly 
pointed out the crucial role of Cl− depletion, as opposed 
to volume depletion, as the main mechanism maintain-
ing diuretic-induced metabolic alkalosis [32]. Accord-
ing to the Stewart’s approach to acid–base equilibrium, 
metabolic alkalosis is determined either by a reduced 
plasma concentration of non-volatile weak acids or by an 
increased plasma SID [34]. In our study, this alteration 
appeared associated with an increased plasma SID, due to 
a reduction in plasma [Cl−] [35]. During the 8-h period, 
median urinary [Cl−] significantly increased as compared 
to baseline, and as compared to baseline plasma [Cl−], 
mainly due to the first 3-h period, in which we observed 
an early peaked urinary [Cl−], and a slower decrement, 
as compared to urinary [Na+] time course. Similarly, in 
patients receiving multiple doses, median urinary [Cl−] 
tended to be higher than baseline plasma [Cl−], likely 
resulting from the cumulative effect of repetitive admin-
istrations, which rapidly increase urinary [Cl−].
Which are the mechanisms underlying the higher uri-
nary [Cl−] excretion rate, as dissociated from [Na+], as 
the key factor generating hypochloremic metabolic alka-
losis? First, the acute “switching-off” of the Henle’s loop 
unveils the quality of the pre-urine originating at the end 
of the proximal tubule, which may acutely reach the end 
of the nephron as unmodified. Along the proximal tubule, 
luminal [Cl−] increases to levels higher than plasma [Cl−] 
because of a different Cl− permeability of the luminal 
Table 3 Plasmatic acid–base equilibrium before  and 
after furosemide administration
Data are reported as median value and interquartile ranges before the first 
and after the last intravenous administration of furosemide for the subgroup 
of patients receiving multiple administrations (multiple-dose group, n = 
11). Total dose of furosemide averaged 38±17 mg, and observation period 
lasted 22 ± 13 h. Paired t test or Wilcoxon signed rank test was performed, as 
appropriate
PaCO2 arterial partial pressure of carbon dioxide, HCO3
− bicarbonate 
concentration, BE base excess, SID strong ion difference, Na+ sodium 
concentration, K+ potassium concentration, Cl− chloride concentration
Before After p
pH 7.43 (7.40–7.46) 7.46 (7.43–7.48) 0.014
PaCO2 (mmHg) 40 (38–43) 41 (39–45) 0.36
HCO3
− (mmol/L) 26.6 (25.3–28.3) 29.0 (28.5–30.6) 0.002
BE (mmol/L) 2.2 (1.5–4.6) 5.5 (4.2–6.8) 0.001
SID (mEq/L) 31 (31–33) 35 (34–36) 0.012
Na+ (mEq/L) 139 (135–142) 140 (137–141) 0.36
K+ (mEq/L) 3.7 (3.5–4.4) 3.8 (3.5–4.2) 0.92
Cl− (mEq/L) 110 (106–111) 106 (105–109) 0.009
Lactate (mEq/L) 0.9 (0.7–2.2) 1.0 (0.7–1.2) 0.24
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membrane, whereas [Na+] remains constant [36]. Sec-
ond, the slow decrement in urinary [Cl−], resulting in an 
increased urinary [Na+]–[Cl−] difference, may be due to 
both a secondary increased activity of aldosterone, pro-
moting a Cl−-independent cortical Na+ reabsorption, and 
a reduced activity of the luminal Cl−/HCO3− exchanger 
pendrin, mediating Cl− reabsorption and HCO3− secre-
tion in type B cortical intercalated cells [37, 38]. We may 
hypothesize that the long-term effects of furosemide 
depend on its acute and immediate inhibition on Henle’s 
loop, unveiling the activity of nephron proximal tubules, 
which, as an additive effect of sequential administrations, 
is responsible of the long-term effects observed.
Our study has certain limitations. First, the sample 
size included is limited, thereby preventing us to fully 
investigate the possible pathophysiologic mechanisms 
underlying the urinary electrolyte alterations observed. 
Second, due to the retrospective and observational 
nature of the study, we cannot exclude the effects of pos-
sible confounding factors, which we were not able to 
control. Nonetheless, the consistency of the urinary data 
observed supports the solidity and the biological plausi-
bility of the findings observed. Third, since plasma creati-
nine is clinically assessed once daily, GFR was estimated, 
and not directly calculated, therefore partially limit-
ing the accuracy of electrolyte Fe calculations. Finally, 
no direct data were obtained on the activation of either 
ANP/BNP or the renin–angiotensin–aldosterone system 
in parallel with furosemide administration.
Our findings may have also some clinical implica-
tions, which warrant further verifications. First, the renal 
response to furosemide observed in patients with normal 
renal function provides a pathophysiological rationale for 
the furosemide stress test to early detect AKI [5], espe-
cially when the injury deemed responsible for renal fail-
ure is located at the proximal tubular level [39]. Similarly, 
the acute response observed after furosemide may unveil 
patient Na+-retaining or Na+-excretive state independ-
ent of Henle’s loop activity, thereby helping in tailoring 
patient hemodynamic management. The late increase in 
urinary NH4+ potentially associated with an aldosterone-
induced increase in H+-ATPase activity may suggest an 
increased renal O2 consumption following furosemide, 
in contrast to previous findings [14, 40], which may warn 
about the use of furosemide in clinical condition at risk of 
AKI. Finally, our findings highlight the importance of the 
increased urinary [Cl−] excretion rate as the key mecha-
nism generating diuretic-induced metabolic alkalosis. A 
real-time urinary electrolyte monitoring may represent 
a potential novel tool to elucidate the specific effects of 
loop-diuretics in ICU patients, while clarifying its vari-
able efficacy and helping in better tailoring patient hemo-
dynamics therapy.
Conclusion
In this study, for the first time, we accurately describe 
in surgical ICU patients with relatively normal renal 
function the urinary electrolyte excretion profile dur-
ing the acute phase following the administration of an 
intravenous bolus of furosemide. Low-dose furosemide 
administration immediately modifies urinary electrolyte 
excretion rates, likely in relation to the ongoing proximal 
tubular activity and patients baseline clinical character-
istics, both unveiled by its inhibitory action on Henle’s 
loop. Such effects, when cumulative, found the bases for 
the long-term acid–base alterations observed. Real-time 
urinary electrolyte monitoring may represent an inter-
esting and useful tool for better tailoring patient diuretic 
and hemodynamic therapies.
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